Neurotech Insights
September 30, 2007
Inside This Issue: Bipolar Disorder
Top News Alerts: Product Updates, Deals & Financings
Featured Topic: Bipolar Disorder Diagnosis and Treatment
Featured Company: Evotec (FSE:EVT)
Subscribe now to access hundreds of articles covering developments in drugs, devices and diagnostics for the brain and nervous system.
Market Highlights: NeuroInsights and NASDAQ Launch Neurotech Index
This month NeuroInsights launched a new neurotech tracking index in collaboration with NASDAQ, called the NASDAQ NeuroInsights Neurotech Index which lists under the symbol NERV. The index is substantially different from NeuroInsights’ previous index which was a representative sample of stocks across the industry. NERV is inclusive of all neurotech companies that meet certain market criteria and have more than 50% of current revenues or an estimated 50% of R&D investment in neurotech. While 61 companies currently qualify as neurotech companies on the three major exchanges according to NeuroInsights, components must also meet minimum market criteria defined by NASDAQ to ensure that viable and liquid ETF products can be created from the index, including a $200 million market cap and 100,000 shares average daily trading volume (See Index Components, page 16; See Neurotech Insights Special Index Edition for full details). NASDAQ is in discussions with financial institutions to create tradable products based on the index. We will keep readers appraised when these products become available...
Diagnosis of Bipolar Disorder on the Rise
Also called manic-depression, bipolar is characterized by episodes of depression alternating with or overlaid by symptoms of mania. Mania is characterized by intense feelings of well-being, elation, and exuberance often coupled with irritability or overt hostility. There is a hugely inflated self-esteem with feelings of grandiosity. Patients often dress in a dazzling and colorful way, their thoughts are racing and their speech is rapid, constant, and impossible to interrupt. Attention shifts quickly from one subject to another and patients are easily distracted. During the episode there is a lack of insight and judgement. Buying sprees, binges, sexual indiscretions, and irresponsible business decisions and investments are common. In many patients, levels of activity are extremely high and they become prone to accidents and trouble with law enforcement. While lithium is the mainstay therapy, antidepressants, antipsychotics, and anticonvulsants are often prescribed. Several new treatments are in development...
Evotec: Renovis Acquisition Solidifies CNS pipeline
Evotec (FSE: EVT), a German company founded in 1993, originally leveraged technology for high throughput screening to work with big pharma partners, including Novartis, Roche, and Pfizer. Evotec’s recent implementation of a new strategic direction to become a CNS drug discovery company has been surprisingly swift and effective. The company now has three products in clinical testing, a rich pipeline of preclinical candidates, a strong cash position, and a slew of upcoming announcements ...
Subscribe Now:
|
Neurotech Insights subscription includes:
- Monthly newsletter containing the latest product development news, deals, and feature stories
- Access to a searchable web archive of articles, companies and investors (NEW!)
Contact us for an enterprise license, academic discounts and NIO member discounts at (415)229-3225.
|
|
